Bio-Rad Laboratories, Inc. Class A
(NYSE: BIO)

Bio-Rad Laboratories, Inc. (Bio-Rad), manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics.. As of December 31, 2011, the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries. In January 2013, the Company purchased AbD Serotec, a division of MorphoSys AG. In April 2014, Bio-Rad Laboratories Inc purchased GnuBIO, Inc.

299.790 -

+2.080 (+0.70%)
Range 294.820 - 302.590   (2.64%)
Open 297.520
Previous Close 297.710
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume 290,883
Value 45,151,251
Remark -
Delayed prices. Updated at 29 Jan 2026 09:00.
Data powered by
View All Events

About Bio-Rad Laboratories A

Bio-Rad Laboratories, Inc. (Bio-Rad), manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics.. As of December 31, 2011, the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries. In January 2013, the Company purchased AbD Serotec, a division of MorphoSys AG. In April 2014, Bio-Rad Laboratories Inc purchased GnuBIO, Inc.

Loading Chart...

Please login to view stock data and analysis